Skip to main content

Table 1 Characteristics of included trials

From: Treatment of chronic HCV genotype 1 infection with telaprevir: a Bayesian mixed treatment comparison of fixed-length and response-guided treatment regimens in treatment-naïve and –experienced patients

Trial

Treatment experience

Treatment type

Overall treatment duration (weeks) #

Treatment group

No of patients

Age (median)

Male sex no (%)

HCV genotype 1b no (%)

TVR treatment (weeks)

Peg-IFN-α dose (weeks)

RBV dose (mg/d)

[16] McHutchison et al. 2009

Naïve

RGT

12

E

17

49

12 (71)

6 (35)

12

α2a: 180 μg

1000-1200

RGT

24

D

79

49

54 (68)

17 (22)

12

α2a: 180 μg

1000-1200

FLT

48

B

79

50

48 (61)

27 (34)

12

α2a: 180 μg

1000-1200

Control

48

A

75

49

43 (57)

20 (27)

none

α2a: 180 μg

1000-1200

[14] Hezode et al. 2009

Naïve

RGT

12

E

82

44

49 (60)

45 (55)

12

α2a: 180 μg

1000-1200

RGT

24

D

81

46

54 (67)

50 (62)

12

α2a: 180 μg

1000-1200

RGT

12

NI

78

45

43 (55)

38 (49)

12

α2a: 180 μg

none

Control

48

A

82

45

46 (56)

45 (55)

none

α2a: 180 μg

1000-1200

[11] McHutchison et al. 2010

Experienced

FLT

24

C

115

51

78 (68)

33 (29)

12

α2a: 180 μg

1000-1200

FLT

48

B

113

52

80 (71)

42 (37)

24

α2a: 180 μg

1000-1200

FLT

24

NI

111

53

72 (65)

36 (32)

24

α2a: 180 μg

none

Control

48

A

114

50

76 (67)

34 (30)

none

α2a: 180 μg

1000-1200

[10] Jacobson et al. 2011

Naïve

RGT

24 (+24)

D

363

49

214 (59)

149 (41)

12

α2a: 180 μg

1000-1200

RGT

24 (+24)

NI

364

49

211 (58)

151 (41)

8

α2a: 180 μg

1000-1200

Control

48

A

361

49

211 (58)

151 (42)

none

α2a: 180 μg

1000-1200

[13] Zeuzem et al.

Experienced

FLT

48

B

266

51

183 (69)

121 (45)

12

α2a: 180 μg

1000-1200

FLT

48

NI

264

51

189 (72)

115 (44)

16

α2a: 180 μg

1000-1200

Control

48

A

132

50

88 (67)

59 (45)

none

α2a: 180 μg

1000-1200

[17] Sherman et al. 2011

Naïve

RGT

24 (+24)

D

221

NA

NA

NA

12

α2a: 180 μg

1000-1200

FLT

48

B

219

NA

NA

NA

12

α2a: 180 μg

1000-1200

[15] Kumada et al. 2012

Naïve

FLT

24

C

126

53

66 (52)

124 (98)

12

α2b: 1.5 μg/kg

600-1000

Control

48

A

63

55

33 (52)

63 (100)

none

α2b: 1.5 μg/kg

600-1000

  1. No: number; TVR: telaprevir; mg: milligram; d: day; RBV: ribavirin; RGT: response-guided treatment; FLT: fixed-length treatment; control: standard treatment; NI: not included; NA: not available; *pseudo-groups merged from original dosing; # in RGT-regimens patients that did not achieve extended rapid-virological-response (eRVR) within the first 4–12 weeks undergo treatment of overall 48-weeks.